Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

This trial is testing a combination of two drugs — tipifarnib and naxitamab — for children and young adults with neuroblastoma (a type of cancer that starts in nerve tissue, usually in young children) that has returned or stopped responding to treatment. Both drugs work on different pathways to fight cancer cells. **You may be eligible if...** - You were diagnosed with neuroblastoma at or before age 21 and are currently older than 12 months - Your cancer has relapsed (come back) or is refractory (not responding to treatment) - Your cancer has been confirmed by pathology at some point in your treatment history - Disease assessment has been performed within 4 weeks before starting the study drug **You may NOT be eligible if...** - Your tumor has not been pathologically confirmed as neuroblastoma - You have other serious health conditions that prevent participation - You have recently received certain other treatments and have not had adequate recovery time Talk to your doctor to see if this trial is right for you.